Literature DB >> 16876991

The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?

Sunil R Lakhani1, Werner Audretsch, Anne-Marie Cleton-Jensen, Bruno Cutuli, Ian Ellis, Vincenzo Eusebi, Marco Greco, Richard S Houslton, Christiane K Kuhl, John Kurtz, Jose Palacios, Hans Peterse, France Rochard, E Rutgers.   

Abstract

Lobular carcinoma in situ was first described over 60 years ago. Despite the long history, it continues to pose significant difficulties in screening, diagnosis, management and treatment. This is partly due its multi-focal and bilateral presentation, an incomplete understanding of its biology and natural history and perpetuation of misconceptions gathered over the last decades. In this review, the working group on behalf of EUSOMA has attempted to summarise the current thinking and management of this interesting lesion.

Entities:  

Mesh:

Year:  2006        PMID: 16876991     DOI: 10.1016/j.ejca.2006.03.019

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  Preinvasive breast cancer.

Authors:  Dennis C Sgroi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

2.  A case of lobular carcinoma in situ presenting as a solid mass.

Authors:  X Zhang; N Hanamura; M Yamasita; Y Kashikura; T Ogawa; S Taizo
Journal:  Br J Radiol       Date:  2011-03       Impact factor: 3.039

3.  Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.

Authors:  Christoph Thomssen; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2010-10-27       Impact factor: 2.860

4.  Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast.

Authors:  Nehmat Houssami; Linn A Abraham; Tracy Onega; Laura C Collins; Brian L Sprague; Deirdre A Hill; Diana L Miglioretti
Journal:  Breast Cancer Res Treat       Date:  2014-05-07       Impact factor: 4.872

5.  Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS.

Authors:  Xiaoxian Li; Mary R Schwartz; Jae Ro; Candice R Hamilton; Alberto G Ayala; Luan D Truong; Qihui Jim Zhai
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Authors:  Yunn-Yi Chen; Eun-Sil Shelley Hwang; Ritu Roy; Sandy DeVries; Joseph Anderson; Chrystal Wa; Patrick L Fitzgibbons; Timothy W Jacobs; Gaetan MacGrogan; Hans Peterse; Anne Vincent-Salomon; Taku Tokuyasu; Stuart J Schnitt; Frederic M Waldman
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

7.  Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia.

Authors:  Aphrodite Nonni; Flora Zagouri; Theodoros N Sergentanis; Andreas C Lazaris; Efstratios S Patsouris; George C Zografos
Journal:  Virchows Arch       Date:  2007-10-09       Impact factor: 4.064

8.  Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.

Authors:  Robin M Ciocca; Tianyu Li; Gary M Freedman; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2008-05-28       Impact factor: 5.344

9.  Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.

Authors:  Rita A Sakr; Michail Schizas; Jose V Scarpa Carniello; Charlotte K Y Ng; Salvatore Piscuoglio; Dilip Giri; Victor P Andrade; Marina De Brot; Raymond S Lim; Russell Towers; Britta Weigelt; Jorge S Reis-Filho; Tari A King
Journal:  Mol Oncol       Date:  2015-11-14       Impact factor: 6.603

10.  Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.

Authors:  Douglas S Gomes; Simone S Porto; Rafael M Rocha; Helenice Gobbi
Journal:  Diagn Pathol       Date:  2013-07-09       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.